ASCO: LDCT lung cancer screening model will up diagnoses

Share this content:
ASCO: Low-Dose CT Lung CA Screening Recs Will Up Diagnoses
ASCO: Low-Dose CT Lung CA Screening Recs Will Up Diagnoses

(HealthDay News) -- Implementation of the U.S. Preventive Services Task Force recommendations for low-dose computed tomography (LDCT) lung cancer screening is expected to increase lung cancer diagnoses and increase Medicare expenditure. These findings have been released in advance of presentation at the annual meeting of the American Society of Clinical Oncology, to be held from May 30 to June 3 in Chicago.

Joshua A. Roth, Ph.D., M.H.A., from the Fred Hutchinson Cancer Research Center in Seattle, and colleagues developed a model to forecast the clinical, resource, and budget impact of implementing annual LDCT lung cancer screening in patients aged 55 to 80 years with a 30 pack-year smoking history. The impact of screening was estimated in two scenarios: complete implementation, with screening offered to all eligible patients in all years, and phase implementation, with the proportion of eligible patients offered screening each year increasing by 20 percent.

The researchers found that screening resulted in 141,000 more lung cancers detected with the complete implementation scenario, and 101,000 more with the phased implementation scenario (mostly stage I cancers). The complete and phased implementation scenarios were expected to result in 37.5 and 22.4 million more LDCT scans, respectively, and increased expenditure of $27.4 billion and $17.6 billion, respectively.

"If we can diagnose lung cancers at an earlier stage, patients can be treated far more effectively and survival prognosis is much better," Roth said in a statement.

The study was funded by Genentech.

Press Release
More Information

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs